Results 21 to 30 of about 55,815 (216)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

BMC Cancer, 2017
Background Sorafenib and transarterial chemoembolization (TACE) are recommended therapies for advanced hepatocellular carcinoma (HCC), but their combined efficacy remains unclear.
Fei-Xiang Wu, Jie Chen, Tao Bai, Shao-Liang Zhu, Tian-Bo Yang, Lu-Nan Qi, Ling Zou, Zi-Hui Li, Jia-Zhou Ye, Le-Qun Li   +9 more
doaj   +1 more source

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). [PDF]

PLoS ONE, 2014
Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event. This study aimed to examine whether the toxicity of sorafenib and sunitinib for human keratinocytes was associated with inhibiting signal transduction and activator of
Kazuhiro Yamamoto, Atsushi Mizumoto, Kohji Nishimura, Atsushi Uda, Akira Mukai, Kazuhiko Yamashita, Manabu Kume, Hiroo Makimoto, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Midori Hirai   +12 more
doaj   +1 more source

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

Cancer Biology & Medicine, 2022
Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance.
Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen, Jinbao Liu   +12 more
doaj   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. [PDF]

PLoS ONE, 2013
The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC).
Wei-Chien Huang, Yi-Ling Hsieh, Chao-Ming Hung, Pei-Hsuan Chien, Yu-Fong Chien, Lei-Chin Chen, Chih-Yen Tu, Chia-Hung Chen, Sheng-Chieh Hsu, Yueh-Ming Lin, Yun-Ju Chen   +10 more
doaj   +1 more source

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BMC Cancer, 2018
Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications.
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang   +9 more
doaj   +1 more source

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis

Journal of Experimental & Clinical Cancer Research, 2023
Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo   +13 more
doaj   +1 more source

Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.

PLoS ONE, 2021
Background and aimAs a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems.
Luping Gao, Yuji Morine, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki, Mitsuo Shimada   +8 more
doaj   +1 more source

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

Frontiers in Pharmacology, 2020
PurposeTo investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).Materials and MethodsThis retrospective study examined 50 ...
Ying Wu, Ying Wu, Han Qi, Han Qi, Fei Cao, Fei Cao, Lujun Shen, Lujun Shen, Shuanggang Chen, Shuanggang Chen, Lin Xie, Lin Xie, Tao Huang, Tao Huang, Ze Song, Danyang Zhou, Danyang Zhou, Weijun Fan, Weijun Fan   +18 more
doaj   +1 more source